Innate Pharma Files Routine 6-K with SEC
Ticker: IPHYF · Form: 6-K · Filed: Jul 25, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jul 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, routine-disclosure, foreign-private-issuer
TL;DR
Innate Pharma filed a 6-K, just a routine check-in with the SEC, no major news.
AI Summary
On July 25, 2024, Innate Pharma SA filed a Form 6-K, reporting its status as a foreign private issuer. The filing does not contain specific financial figures or operational updates but serves as a routine disclosure to the SEC.
Why It Matters
This filing indicates Innate Pharma is complying with its reporting obligations as a foreign private issuer, which is standard for companies listed on US exchanges.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new material information that would impact risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- SEC (company) — Securities and Exchange Commission
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes public in its home country, files with a stock exchange, or distributes to its security holders.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is July 25, 2024.
Is Innate Pharma SA filing an annual report with this Form 6-K?
No, Innate Pharma SA is filing a Form 6-K, which is a report of foreign private issuers, and indicates it files annual reports under cover of Form 20-F.
Where is Innate Pharma SA's principal executive office located?
Innate Pharma SA's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does this filing contain specific financial results or operational updates?
No, this Form 6-K filing does not appear to contain specific financial results or operational updates; it is a routine disclosure.
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-07-25 06:06:11
Filing Documents
- a6k-iphx240710.htm (6-K) — 9KB
- exhibit991-240710.htm (EX-99.1) — 15KB
- 0001598599-24-000051.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date July, 25 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive officer